Allergan Hits Back After Valeant Stands By Business Model
Allergan Inc. hit back on Tuesday against Valeant Pharmaceuticals International Inc.'s allegations Allergan lied to its shareholders about Valeant's financial health amid Valeant's attempted $53 billion hostile takeover, dismissing Valeant's counterclaims...To view the full article, register now.
Already a subscriber? Click here to view full article